Development of a Series of Aryl Pyrimidine Kynurenine Monooxygenase Inhibitors as Potential Therapeutic Agents for the Treatment of Huntington’s Disease-Reference-Cited by-同舟云学术

Development of a Series of Aryl Pyrimidine Kynurenine Monooxygenase Inhibitors as Potential Therapeutic Agents for the Treatment of Huntington’s Disease

Published:2015-01-23 Issue:3 Volume:58 Page:1159-1183
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Toledo-Sherman Leticia M.¹,Prime Michael E.²,Mrzljak Ladislav³,Beconi Maria G.¹,Beresford Alan⁴,Brookfield Frederick A.²,Brown Christopher J.²,Cardaun Isabell⁵,Courtney Stephen M.²,Dijkman Ulrike⁶,Hamelin-Flegg Estelle²,Johnson Peter D.²,Kempf Valerie⁷,Lyons Kathy⁸,Matthews Kimberly⁴,Mitchell William L.²,O’Connell Catherine⁴,Pena Paula²,Powell Kendall⁷,Rassoulpour Arash⁶,Reed Laura²,Reindl Wolfgang⁵,Selvaratnam Suganathan²,Friley Weslyn Ward⁷,Weddell Derek A.²,Went Naomi E.²,Wheelan Patricia⁷,Winkler Christin⁵,Winkler Dirk⁵,Wityak John¹,Yarnold Christopher J.²,Yates Dawn⁴,Munoz-Sanjuan Ignacio¹,Dominguez Celia¹

Affiliation:

1. CHDI Management/CHDI Foundation, 6080 Center Drive, Suite 100, Los Angeles, California 90405, United States

2. Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon, OX14 4RZ, U.K.

3. CHDI Management/CHDI Foundation, 155 Village Boulevard, Suite 200, Princeton, New Jersey 08540, United States

4. Charles River Laboratories, Chesterford Research Park, Saffron Walden, Essex, U.K.

5. Evotec AG, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany

6. Brains On-Line LLC, 7000 Shoreline Court, South San Francisco, California 94080, United States

7. Tandem Laboratories, 2202 Ellis Road, Durham, North Carolina 27703, United States

8. Kathryn A. Lyons, P.O. Box 64, Holland, New York 14080, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm501350y

Reference68 articles.

1. Genetics and Neuropathology of Huntington's Disease

2. The structural correlates of functional deficits in early huntington's disease

3. Role of Tetrabenazine for Huntington's Disease-Associated Chorea

4. Kynurenines in the mammalian brain: when physiology meets pathology

5. Kynurenines in the CNS: recent advances and new questions

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis of 1-Methylcyclopropyl Aryl Ethers from Phenols Using an Alkenylation-Cyclopropanation Sequence;The Journal of Organic Chemistry;2023-08-24

2. Validation of LC–MS/MS methods for quantitative analysis of kynurenine pathway metabolites in human plasma and cerebrospinal fluid;Bioanalysis;2023-06

3. Therapeutic potential of targeting kynurenine pathway in neurodegenerative diseases;European Journal of Medicinal Chemistry;2023-05

4. Pyrimidine analogues for the management of neurodegenerative diseases;European Journal of Medicinal Chemistry Reports;2022-12

5. Kynurenine‐3‐monooxygenase (KMO): From its biological functions to therapeutic effect in diseases progression;Journal of Cellular Physiology;2022-09-11